Sandoz Finalizes USD 170 Million Purchase of Coherus BioSciences' Biosimilar Drug CIMERLI* (ranibizumab-eqrn) in the US

BioNTech and DualityBio have launched a critical Phase 3 study for their therapeutic agent BNT323/DB-1303, targeting advanced breast cancer.

NK CellTech has received the green light from the Food and Drug Administration (FDA) to initiate clinical trials for its therapy, NK010.

ProMIS Neurosciences Inc. has declared the identification of a premier vaccine contender, PMN400.

AC Immune SA to Reclaim Global Ownership of Two Therapeutic Antibodies Post-Partnership with Genentech and Roche.

Ionis reveals encouraging preliminary outcomes from the third phase of the OASIS-HAE trial, examining the experimental compound donidalorsen in individuals with genetic angioedema.

In the CheckMate -8HW study, the combination of Opdivo and Yervoy reduced the likelihood of disease advancement or fatality in patients with MSI-H/dMMR metastatic colorectal cancer by 79% when compared to chemotherapy.

BALVERSA® gains complete sanction from the U.S. FDA to cure bladder cancer in advanced or metastatic stages with specific genetic changes.

Merck Sharp & Dohme (MSD) and Harpoon Therapeutics announced a deal for MSD to purchase Harpoon at $23/share, totaling around $680 million in equity.

Novartis Lutathera® substantially lessens the risk of gastroenteropancreatic neuroendocrine tumors worsening or mortality by 72%.

Bristol Myers Squibb (BMS) and RayzeBio announced a definitive merger, with BMS acquiring RayzeBio for $62.50/share in a deal valued at about $4.1 billion, netting $3.6 billion after accounting for RayzeBio's $500 million cash.

At the 2024 ASCO GI Cancers Symposium, CARsgen Therapeutics presented study results for "satri-cel" (CT041), a Claudin18.2-targeted CAR-T therapy.